Vor Biopharma, Inc. (VOR) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Vor Biopharma, Inc. (VOR) Healthcare & Pipeline Overview

Vor Biopharma, a clinical-stage biotech firm, pioneers engineered hematopoietic stem cell (eHSC) therapies, notably VOR33, designed to treat AML and other blood cancers. Their innovative approach involves modifying stem cells to enhance the effectiveness of targeted cancer treatments, positioning them within the competitive biotechnology landscape.

What Is the Investment Thesis for VOR?

Vor Biopharma's investment thesis centers on its innovative eHSC platform, particularly the VOR33 program targeting AML. The Phase 1/2 clinical trials for VOR33 represent a key value driver, with positive data potentially leading to accelerated regulatory pathways and increased investor confidence. The company's approach of combining eHSCs with targeted therapies like CAR-T cells could significantly improve treatment efficacy and reduce toxicity, addressing a critical unmet need in hematological malignancies. Key risks include clinical trial setbacks, regulatory hurdles, and competition from established therapies. Successful clinical development and strategic partnerships are vital for realizing the full potential of Vor Biopharma's technology.

Based on FMP financials and quantitative analysis

VOR Key Highlights

VOR33 is in Phase 1/2 clinical trials for the treatment of acute myeloid leukemia (AML) and other hematological malignancies.

• The company's eHSCs lack CD33, a protein that is expressed by AML blood cancer cells.
• Vor Biopharma has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases.
• The company's market capitalization is $0.11 billion, reflecting investor sentiment and growth potential.
• Vor Biopharma employs 159 individuals, indicating a focused and specialized workforce.

Who Are VOR's Competitors?

VOR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are VOR's Key Strengths?

Innovative eHSC technology platform.

• Lead product candidate (VOR33) in clinical trials.
• Experienced management team.
• Collaboration with Akron BioProducts.

What Are VOR's Weaknesses?

Clinical-stage company with no approved products.

• High cash burn rate.
• Dependence on the success of VOR33.
• Limited commercial infrastructure.

What Could Drive VOR Stock Higher?

VOR catalyst: Data readout from the Phase 1/2 clinical trial of VOR33 in AML patients expected in Q4 2026.

• Enrollment of patients in the Phase 1/2 clinical trial of VOR33.
• Advancing preclinical development of next-generation eHSC therapies.
• Potential strategic partnerships with pharmaceutical companies by mid-2027.

What Are the Key Risks for VOR?

Negative return on equity (-91.6%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $42.2M recently.
• Clinical trial failures or delays could negatively impact the company's stock price.
• Regulatory hurdles and delays in obtaining FDA approval.
• Competition from established therapies and other emerging technologies.
• High cash burn rate and the need for additional financing.
• Patent challenges or loss of intellectual property protection.

What Are the Growth Opportunities for VOR?

• Expansion of VOR33 into Additional Hematological Malignancies: Vor Biopharma has the opportunity to expand the application of VOR33 beyond AML to other hematological malignancies, such as myelodysplastic syndromes (MDS) and acute lymphoblastic leukemia (ALL). These indications represent a significant market opportunity, potentially doubling the addressable patient population. Success in these additional indications would solidify VOR33's position as a versatile platform for treating various blood cancers. This expansion could begin as early as 2027, pending positive clinical data from the ongoing trials.
• Development of Next-Generation eHSC Therapies: Vor Biopharma can leverage its expertise in eHSC engineering to develop next-generation therapies targeting different cancer-specific proteins or incorporating additional functionalities, such as enhanced immune modulation. This could involve creating eHSCs that express specific cytokines or co-stimulatory molecules to further enhance the anti-cancer immune response. The market for advanced cell therapies is projected to reach $50 billion by 2030, offering substantial growth potential.
• Strategic Partnerships with Pharmaceutical Companies: Collaborating with larger pharmaceutical companies to co-develop and commercialize VOR33 or other eHSC therapies represents a significant growth opportunity. These partnerships can provide access to resources, expertise, and established commercial infrastructure, accelerating the development and market penetration of Vor Biopharma's products. Such partnerships could also lead to significant upfront payments, milestone payments, and royalty streams, bolstering the company's financial position.
• Advancement of Targeted Therapies in Combination with VOR33: Vor Biopharma can focus on developing or partnering with companies that have targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates, to be used in combination with VOR33. This synergistic approach could lead to more effective and durable responses in patients with AML and other hematological malignancies. The market for targeted cancer therapies is expected to reach $150 billion by 2028, highlighting the potential for significant revenue generation.
• Geographic Expansion into International Markets: Expanding clinical trials and eventual commercialization efforts into international markets, such as Europe and Asia, represents a substantial growth opportunity. These markets offer access to larger patient populations and diverse healthcare systems, potentially accelerating the adoption of Vor Biopharma's therapies. This expansion would require establishing strategic partnerships with local distributors and navigating regulatory pathways in each region, but the long-term benefits could be significant.

What Are VOR's Competitive Advantages?

• Proprietary eHSC engineering technology.
• Patent protection for VOR33 and other eHSC therapies.
• Clinical data demonstrating the safety and efficacy of VOR33.
• Collaboration agreements with key partners like Akron BioProducts.

What Does VOR Do?

Vor Biopharma Inc., founded in 2015 and headquartered in Cambridge, Massachusetts, is a clinical-stage biotechnology company dedicated to transforming the treatment of cancer through its novel engineered hematopoietic stem cell (eHSC) therapies. The company's core technology revolves around engineering hematopoietic stem cells to lack specific proteins, thereby making cancer cells more susceptible to targeted therapies. Their lead product candidate, VOR33, an eHSC product, is currently in Phase 1/2 clinical trials for the treatment of acute myeloid leukemia (AML) and other hematological malignancies. VOR33 eHSCs are engineered to lack CD33, a protein commonly expressed by AML cells, allowing targeted therapies like CAR-T cells, bispecific antibodies, and antibody-drug conjugates to selectively eliminate cancer cells while sparing the engineered healthy cells. This innovative approach aims to improve treatment outcomes and reduce the toxic side effects associated with traditional cancer therapies. Vor Biopharma also collaborates with Akron BioProducts to develop and manufacture cGMP nucleases, essential components in their eHSC engineering process. By focusing on precision medicine and leveraging cutting-edge technologies, Vor Biopharma seeks to establish a new paradigm in cancer treatment, offering more effective and less toxic options for patients battling blood cancers.

What Products and Services Does VOR Offer?

• Develop engineered hematopoietic stem cell (eHSC) therapies.
• Engineer stem cells to lack specific proteins found on cancer cells.
• Create VOR33, an eHSC product candidate for treating AML.
• Conduct Phase 1/2 clinical trials for VOR33.
• Collaborate with Akron BioProducts to manufacture cGMP nucleases.
• Target blood cancers with eHSCs and therapies like CAR-Ts and bispecific antibodies.

How Does VOR Make Money?

• Develop and patent novel eHSC therapies.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from the FDA and other agencies.
• Potentially partner with pharmaceutical companies for commercialization.
• Generate revenue through product sales and licensing agreements.

What Industry Does VOR Operate In?

Vor Biopharma operates within the dynamic and competitive biotechnology industry, which is characterized by rapid innovation and high-risk, high-reward ventures. The market for cancer therapies is substantial and growing, driven by an aging population and increasing cancer incidence rates. Vor Biopharma's focus on eHSC therapies positions it within the innovative segment of cell and gene therapy, competing with companies developing CAR-T cell therapies, bispecific antibodies, and other targeted cancer treatments. The company's success hinges on its ability to demonstrate clinical efficacy and safety, navigate regulatory pathways, and secure strategic partnerships in a landscape dominated by larger pharmaceutical companies.

Who Are VOR's Key Customers?

• Cancer patients, specifically those with acute myeloid leukemia (AML).
• Hospitals and oncology clinics that administer cancer treatments.
• Pharmaceutical companies seeking innovative cancer therapies.
• Research institutions involved in cancer research and clinical trials.

Return on equity for Vor Biopharma, Inc. stands at -91.6%, a gauge of how efficiently it converts shareholder capital into profit. VOR trades at a trailing price-to-earnings ratio of 2.00, below the Healthcare sector average of ~23x. Its free cash flow yield is -11.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 19.15 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 50.0%, the inverse of the P/E and a quick read on earnings relative to price.

Vor Biopharma, Inc. (VOR) Valuation Context

Valued at $1.28B, VOR is classified as a small-cap stock. Relative to its peer group, VOR's quantitative score of 53/100 is below the peer average of 64/100.

Company Profile

Vor Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Jean-Paul Kress. VOR has traded publicly since 2021.

Vor Biopharma, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 2.47 places it in the grey zone, a middle ground that warrants monitoring.

Wall Street analysts project Vor Biopharma, Inc. revenue of about $4.2M for fiscal 2026, with EPS near $-6.50. The estimate reflects 7 contributing analysts.

Over the past six months, Vor Biopharma, Inc. insiders filed 27 SEC Form 4 transactions — 17 sales and 10 purchases. On net that is roughly 2.5M shares disposed (about $42.2M), a signal worth weighing alongside the fundamentals.

VOR Financials

VOR Latest News

VOR Analyst Consensus

VOR MoonshotScore

What Investors Ask About Vor Biopharma, Inc. (VOR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources